Prognostic Value of Quantitative [ 18 F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma

• Published in: Diagnostics (Basel) Vol. 11; no. 12; p. 2271
• Main Authors: Kalisvaart, Gijsbert M, Grootjans, Willem, Bovée, Judith V M G, Gelderblom, Hans, van der Hage, Jos A, van de Sande, Michiel A J, van Velden, Floris H P, Bloem, Johan L, de Geus-Oei, Lioe-Fee
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04.12.2021; MDPI
• Subjects: [18F]FDG-PET; Medical prognosis; Metabolism; Metastasis; metastatic soft tissue sarcoma; Patients; prognosis; Radiation therapy; Sarcoma; Netherlands; metastatic soft tissue sarcoma; prognosis; [18F]FDG-PET
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics11122271

Prognostic biomarkers are pivotal for adequate treatment decision making. The objective of this study was to determine the added prognostic value of quantitative [ F]FDG-PET features in patients with metastases from soft tissue sarcoma (STS). Patients with metastases from STS, detected by (re)staging [ F]FDG-PET/CT at Leiden University Medical Centre, were retrospectively included. Clinical and histopathological patient characteristics and [ F]FDG-PET features (SUVmax, SUVpeak, SUVmean, total lesion glycolysis, and metabolic tumor volume) were analyzed as prognostic factors for overall survival using a Cox proportional hazards model and Kaplan-Meier methods. A total of 31 patients were included. SUVmax and SUVpeak were significantly predictive for overall survival (OS) in a univariate analysis ( = 0.004 and = 0.006, respectively). Hazard ratios (HRs) were 1.16 per unit increase for SUVmax and 1.20 per unit for SUVpeak. SUVmax and SUVpeak remained significant predictors for overall survival after correction for the two strongest predictive clinical characteristics (number of lesions and performance status) in a multivariate analysis ( = 0.02 for both). Median SUVmax and SUVpeak were 5.7 and 4.9 g/mL, respectively. The estimated mean overall survival in patients with SUVmax > 5.7 g/mL was 14 months; otherwise, it was 39 months ( < 0.001). For patients with SUVpeak > 4.9 g/mL, the estimated mean overall survival was 18 months; otherwise, it was 33 months ( = 0.04). In this study, SUVmax and SUVpeak were independent prognostic factors for overall survival in patients with metastases from STS. These results warrant further investigation of metabolic imaging with [ F]FDG-PET/CT in patients with metastatic STS.